Close
Show

Research Insight

This unique section brings insights into latest break-through in Pharma Research, laboratory investigations, studies and results of clinical trials. These insights from senior professionals in R&D laboratories, Institutes would help the Pharma Professionals develop refined perspective on the trends in the Pharma Market and the issues concerning the domain.

Rivaroxaban plus aspirin improves outcomes in stable cardiovascular disease (COMPASS)


Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with stable...

Enhancing process safety and efficiency in the pharmaceutical industry with check Weighing solutions


A look at how pharmaceutical manufacturers can benefit from the use of dynamic checkweighing technology...

ViscoTec Pharma Dispenser VPHD on the test


With nearly 140 years of success, Henkel holds globally leading market positions both in the...

Biofortuna reaches key milestones for ReadyPlex blood group


Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has...

Boehringer Ingelheim and Harvard scientists establish a research alliance


Boehringer Ingelheim announced it has established a research collaboration with the Harvard Stem Cell Institute’s...

Mylan Launches First Generic of Nuvigil Tablets


Mylan N.V. announced the U.S. launch of Armodafinil Tablets, 50 mg, 150 mg, 250 mg,...

Allergan Announces Positive Pivotal Trial Results for Oculeve Intranasal Tear Neurostimulator


Allergan plc announced that two pivotal trials of the Oculeve Intranasal Tear Neurostimulator, OCUN-009 and...

Chugai Pharmaceutical Co Ltd announced Efficacy of Actemra Subcutaneous Injection Confirmed in Dose Interval...


Chugai Pharmaceutical Co Ltd announced that "Actemra® Subcutaneous Injection" (Actemra), the humanized antihuman IL-6 receptor...

Novartis announced Major study published in NEJM confirms Ultibro Breezhaler superiority over Sere


FLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung...

Phase III Trial of Regorafenib in Patients with Unresectable Liver Cancer Meets Primary Endpoint...


Bayer announced that a Phase III trial evaluating its oncology compound regorafenib (Stivarga®) for the...